Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports
E Mahase - 2021 - bmj.com
2021•bmj.com
Pfizer's oral antiviral drug paxlovid significantly reduces hospital admissions and deaths
among people with covid-19 who are at high risk of severe illness, when compared with
placebo, the company has reported.The interim analysis of the phase II-III data, outlined in a
press release, included 1219 adults who were enrolled by 29 September 2021. It found that,
among participants who received treatments within three days of covid-19 symptoms
starting, the risk of covid related hospital admission or death from any cause was 89% lower …
among people with covid-19 who are at high risk of severe illness, when compared with
placebo, the company has reported.The interim analysis of the phase II-III data, outlined in a
press release, included 1219 adults who were enrolled by 29 September 2021. It found that,
among participants who received treatments within three days of covid-19 symptoms
starting, the risk of covid related hospital admission or death from any cause was 89% lower …
Pfizer’s oral antiviral drug paxlovid significantly reduces hospital admissions and deaths among people with covid-19 who are at high risk of severe illness, when compared with placebo, the company has reported.
The interim analysis of the phase II-III data, outlined in a press release, included 1219 adults who were enrolled by 29 September 2021. It found that, among participants who received treatments within three days of covid-19 symptoms starting, the risk of covid related hospital admission or death from any cause was 89% lower in the paxlovid group than the placebo group.
bmj.com
